Abstract
The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas. No responses were seen in 18 evaluable patients. Toxicity consisted mainly of nausea/vomiting. It is concluded that oral miltefosine has no activity in soft tissue sarcoma.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Administration, Oral
-
Adolescent
-
Adult
-
Female
-
Humans
-
Male
-
Middle Aged
-
Nausea / chemically induced
-
Phosphorylcholine / administration & dosage
-
Phosphorylcholine / adverse effects
-
Phosphorylcholine / analogs & derivatives*
-
Sarcoma / drug therapy*
-
Soft Tissue Neoplasms / drug therapy*
-
Vomiting / chemically induced
Substances
-
Phosphorylcholine
-
miltefosine